Author name: Sean Lightheart

Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion   Industry-leaders Sunil Shah (CEO, o2h […]

By Sophie Reay Organoids are miniature, three-dimensional (3D) tissue cultures that mimic the structure and function of specific organs. They

Securing research funding is a competitive process. Review panels look for more than just sound science – they’re also seeking

By Sophie Reay, Historically, preclinical testing on animal models formed a critical step in the drug discovery and development pipeline,

As the global biotechnology sector works to extend the reach of life-saving mRNA vaccines, a persistent challenge remains: the carbon-intensive,

At Atelerix, we’re proud to support pioneering work that translates innovative science into real-world patient impact. A recent clinical milestone

Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic preservation technology eliminates

We’re thrilled to share some seriously good news: Atelerix has been shortlisted not once, but twice for the Medilink Healthcare

Newcastle, UK – [17.02.2025] – Atelerix, the pioneering biotech company revolutionising cell preservation, has unveiled BloodReady™, a first-of-its-kind solution that

By Rachel Sanders Preserving cell functionality during storage and transportation is challenging for cell-based therapies as cryopreservation methods can compromise

By Rachel Sanders In scientific research, efficiency and reliability are of the utmost importance, and one of the most persistent

By Sarah Marsh   In an era where environmental consciousness is paramount, the scientific community faces a unique challenge: balancing